Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.30 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.30 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.30 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12282435 | 1.00 | CA2 (0.39) | CA2CA1MGLLALDH1A1TP53 | |
| SCHEMBL12282911 | 0.91 | ESR1 (0.41) | CA2CA1MGLLTP53ESR1 | |
| SCHEMBL12281931 | 0.89 | CA2 (0.35) | CA2CA1LPLLIPGORAI1 | |
| SCHEMBL14379316 | 0.84 | MEN1 (0.48) | CA2CA1MGLLCYP3A4ESR1 | |
| SCHEMBL15462589 | 0.82 | CA1 (0.30) | CA2CA1MGLL | |
| SCHEMBL14379318 | 0.80 | PTGS2 (0.40) | CA2CA1MGLLALDH1A1 | |
| SCHEMBL13792061 | 0.76 | CA2 (0.55) | CA2CA1ALDH1A1TDP1LPL | |
| SCHEMBL18174781 | 0.75 | CYP2A6 (0.60) | CA2CA1ALDH1A1TP53CYP3A4 | |
| SCHEMBL13948976 | 0.73 | CA2 (0.52) | CA2CA1ALDH1A1TDP1 | |
| SCHEMBL9945898 | 0.73 | CA2 (0.60) | CA2CA1MGLLLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148596-A1 | Covalent Organic Frameworks and Methods of Making Same | CORNELL UNIVERSITY (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148596-A1 | Covalent Organic Frameworks and Methods of Making Same | CORNELL UNIVERSITY (US) | 2014-05-29 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011127301-A2 | COVALENT ORGANIC FRAMEWORKS AND METHODS OF MAKING SAME | CORNELL UNIVERSITY (US) | 2011-10-13 | — | — | WO | disclosed |
| US-7279603-B2 | Boron and aluminum compounds in electronic components | MERCK PATENT GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | CA2 3510/4885CA1 4827/4885MGLL 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.